Stereotaxis Q1 operating loss widens to $6 million; revenue falls 15.8% to $6.3 million

STEREOTAXIS INC

STEREOTAXIS INC

STXS

0.00
  • Stereotaxis posted Q1 revenue of USD 6.3 million, down from USD 7.5 million a year earlier, with systems at USD 1.3 million and disposables, service and accessories at USD 5 million.
  • Net loss was USD 5.9 million, little changed from USD 5.8 million, while operating loss widened slightly to USD 6 million from USD 5.9 million.
  • Gross margin was 60%, with recurring revenue gross margin at 66% and system gross margin at 39%; cash and cash equivalents totaled USD 14.6 million with no debt.
  • MAGiC catheter received U.S. FDA approval in January and is being used at multiple sites in the U.S. and Europe, while Synchrony digital operating room system received U.S. FDA clearance in April with initial orders and shipments underway.
  • Signed definitive agreement to acquire Robocath; outlook calls for double-digit 2026 revenue growth with annual revenue expected to surpass USD 40 million, with Q3 and Q4 each expected to exceed USD 10 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stereotaxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121606PRIMZONEFULLFEED9718531) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.